EVEREST: Evaluation of COVID-19 Vaccination Efficacy and Rare Events in Solid Tumours

Not Applicable

Recruiting

• Conditions: Cancer (solid tumour); Cancer - Any cancer

• Registration Number: ACTRN12621001307897
• Lead Sponsor: The Canberra Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-27
• Last Update Posted: 18 October 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Planning to receive the COVID-19 vaccine or
received one dose of COVID-19 vaccine or
within 3 months of completion of COVID-19 vaccination (received two doses of the vaccine)
2. Recipients of either the Pfizer, AstraZeneca or Moderna COVID-19 vaccines
3. Cancer patient cohort: confirmed solid tumour malignancy and:
a.Receiving systemic cancer treatment: cytotoxic therapy, immunotherapy or targeted therapy within two weeks of at least one of the vaccine doses.
b.Targeted therapy includes and is not limited to tyrosine kinase inhibitors e.g. imatinib, cabozantinib, pazopanib, gefitinib, osimertinib; CDK4/6 inhibitors; BRAF/MEK inhibitors
c.Patients receiving hormonal therapy alone will not be eligible for the study.

Exclusion Criteria

1.Beyond 3 months following receipt of second dose of COVID-19 vaccination.
2.Past laboratory confirmed diagnosis of COVID-19 infection (such as nasopharyngeal RT-PCR swab). Routine screening for COVID-19 infection beyond requirements of the local health authority is not required.
3.Concurrent diagnosis of active haematological malignancy.

Study & Design

• Study Type: Observational
• Study Design: Not specified